Literature DB >> 24696061

Preoperative hepatitis B virus DNA level is a risk factor for postoperative liver failure in patients who underwent partial hepatectomy for hepatitis B-related hepatocellular carcinoma.

Gang Huang1, Wan Yee Lau, Feng Shen, Ze-Ya Pan, Si-Yuan Fu, Yun Yang, Wei-Ping Zhou, Meng-Chao Wu.   

Abstract

OBJECTIVE: Our objective was to explore the short-term effects of preoperative serum hepatitis B virus DNA level (HBV DNA) on postoperative hepatic function in patients who underwent partial hepatectomy for hepatitis B-related hepatocellular carcinoma (HCC).
METHODS: The clinical data of 1,602 patients with hepatitis B-related HCC who underwent partial hepatectomy in our department were retrospectively studied. The patients were divided into three groups according to their preoperative HBV DNA levels: group A <200 IU/mL, group B 200-20,000 IU/mL, and group C >20,000 IU/mL. The rates of postoperative complications, especially the rate of postoperative liver failure, were compared.
RESULTS: There were significant differences among the three groups in the rates of postoperative liver failure. On multivariate logistic regression analysis, a high preoperative HBV DNA level was an independent risk factor for postoperative liver failure.
CONCLUSIONS: Preoperative HBV DNA level was a significant risk factor for postoperative hepatic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24696061     DOI: 10.1007/s00268-014-2546-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  29 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

Review 2.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 3.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.

Authors:  Winnie Yeo; Philip J Johnson
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

4.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

Review 5.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

6.  Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms.

Authors:  G J Webster; S Reignat; M K Maini; S A Whalley; G S Ogg; A King; D Brown; P L Amlot; R Williams; D Vergani; G M Dusheiko; A Bertoletti
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

7.  Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation.

Authors:  Zlatko Trobonjaca; Andrea Kröger; Detlef Stober; Frank Leithäuser; Peter Möller; Hansjörg Hauser; Reinhold Schirmbeck; Jörg Reimann
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

8.  High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy.

Authors:  S Zhong; W Yeo; C Schroder; P K S Chan; W-L Wong; W M Ho; F Mo; B Zee; P J Johnson
Journal:  J Viral Hepat       Date:  2004-01       Impact factor: 3.728

9.  Perioperative mortality for management of hepatic neoplasm: a simple risk score.

Authors:  Jessica P Simons; Joshua S Hill; Sing Chau Ng; Shimul A Shah; Zheng Zhou; Giles F Whalen; Jennifer F Tseng
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  6 in total

1.  Impact of Preoperative Hepatitis B Virus Levels on Prognosis After Primary and Repeat Hepatectomies for Hepatocellular Carcinoma Patients-a Retrospective Study.

Authors:  Pin-Gao Yan; Ruo-Yu Wang; Jin Zhang; Wen-Ming Cong; Hui Dong; Hong-Yu Yu; Wan Yee Lau; Meng-Chao Wu; Wei-Ping Zhou
Journal:  J Gastrointest Surg       Date:  2018-01-08       Impact factor: 3.452

2.  Prediction of posthepatectomy liver failure using transient elastography in patients with hepatitis B related hepatocellular carcinoma.

Authors:  Jie-Wen Lei; Xiao-Yu Ji; Jun-Feng Hong; Wan-Bin Li; Yan Chen; Yan Pan; Jia Guo
Journal:  BMC Gastroenterol       Date:  2017-12-29       Impact factor: 3.067

3.  Preoperative aspartate aminotransferase-to-platelet-ratio index as a predictor of posthepatectomy liver failure for resectable hepatocellular carcinoma.

Authors:  Rong-Yun Mai; Jia-Zhou Ye; Zhong-Rong Long; Xian-Mao Shi; Tao Bai; Jie Chen; Le-Qun Li; Guo-Bin Wu; Fei-Xiang Wu
Journal:  Cancer Manag Res       Date:  2019-02-12       Impact factor: 3.989

4.  Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization.

Authors:  Zhen-Xin Chen; Zhi-Wei Jian; Xi-Wen Wu; Jun-Cheng Wang; Jing-Yuan Peng; Xiang-Ming Lao
Journal:  Cancer Med       Date:  2019-07-17       Impact factor: 4.452

5.  Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies/mL.

Authors:  Zhi-Bo Xie; Xiao-Bo Wang; De-Liang Fu; Jian-Hong Zhong; Xia-Wei Yang; Le-Qun Li
Journal:  Onco Targets Ther       Date:  2016-07-25       Impact factor: 4.147

6.  Preliminary experience in laparoscopic resection of hepatic hydatidectocyst with the Da Vinci Surgical System (DVSS): a case report.

Authors:  Haibo Zou; Lanyun Luo; Hua Xue; Guan Wang; Xiankui Wang; Le Luo; Yutong Yao; Guangming Xiang; Xiaolun Huang
Journal:  BMC Surg       Date:  2017-09-11       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.